To evaluate the stability and heterogeneity of cytokine and chemokine profiles in 80 youth with and without HIV-1 infection, we tested plasma samples at repeated visits without antiretroviral therapy. Among nine analytes that were quantified using multiplexing assays, interleukin 10 (IL-10), IL-18, and soluble CD30 persistently showed a positive correlation with HIV-1 viral load (Spearman ρ = 0.40–0.59, p < 0.01 for all). A negative correlation with CD4+ T cell counts (ρ = −0.40 to −0.60, p < 0.01 for all) was also persistent for the three analytes. Analyses restricted to 48 AIDS-free youth (96 visits) yielded similar findings, as did multivariable models in which race, sex, age, body mass index, and time interval between visits were treated as covariates. These relationships reflected two novel features observed for all three analytes. First, their presence in plasma was relatively stable between visits (ρ = 0.50–0.90, p < 0.03), regardless of HIV-1 infection status. Second, pairwise correlation was strong and persistent in HIV-1-seropositive youth (ρ = 0.40–0.59, p < 0.01), but not in HIV-1, seronegatives (p > 0.13). Additional analytes, especially eotaxin/CCL11 and SDF-1β/CXCL12, had no correlation with HIV-1-related outcomes despite their stability between visits. Overall, circulating IL-10, IL-18, and soluble CD30 could partially track unfavorable responses to HIV-1 infection in youth. These markers of persistent immune activation are individually and collectively indicative of HIV-1 pathogenesis.
Get full access to this article
View all access options for this article.
References
1.
GiorgiJV, DetelsR. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin Immunol Immunopathol, 1989; 52:10–18.
2.
RamzaouiS, Jouen-BeadesF, GilbertD, Borsa-LebasF, MichelY, HumbertG, TronF. During HIV infection, CD4+ CD38+ T-cells are the predominant circulating CD4+ subset whose HLA-DR positivity increases with disease progression and whose V beta repertoire is similar to that of CD4+ CD38− T-cells. Clin Immunol Immunopathol, 1995; 77:33–41.
3.
SavarinoA, BottarelF, MalavasiF, DianzaniU. Role of CD38 in HIV-1 infection: An epiphenomenon of T-cell activation or an active player in virus/host interactions?AIDS, 2000; 14:1079–1089.
4.
ChunTW, JustementJS, SanfordC, HallahanCW, PlantaMA, LoutfyM, KottililS, MoirS, KovacsC, FauciAS. Relationship between the frequency of HIV-specific CD8+ T cells and the level of CD38+ CD8+ T cells in untreated HIV-infected individuals. Proc Natl Acad Sci USA, 2004; 101:2464–2469.
5.
ClericiM, ShearerGM. A Th1 → Th2 switch is a critical step in the etiology of HIV infection. Immunol Today, 1993; 14:107–111.
6.
AltfeldM, AddoMM, KreuzerKA, RockstrohJK, DumoulinFL, SchlieferK, LeifeldL, SauerbruchT, SpenglerU. TH1 to TH2 shift of cytokines in peripheral blood of HIV-infected patients is detectable by reverse transcriptase polymerase chain reaction but not by enzyme-linked immunosorbent assay under nonstimulated conditions. J Acquir Immune Defic Syndr, 2000; 23:287–294.
7.
AbramsD, LevyY, LossoMH, BabikerA, CollinsG, CooperDA, DarbyshireJ, EmeryS, FoxL, GordinF, LaneHC, LundgrenJD, MitsuyasuR, NeatonJD, PhillipsA, RoutyJP, TambussiG, WentworthD. Interleukin-2 therapy in patients with HIV infection. N Engl J Med, 2009; 361:1548–1559.
8.
LedermanMM, VeazeyRS, OffordR, MosierDE, DufourJ, MeffordM, PiatakMJr, LifsonJD, SalkowitzJR, RodriguezB, BlauveltA, HartleyO. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science, 2004; 306:485–487.
9.
VangelistaL, SecchiM, LussoP. Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine, 2008; 26:3008–3015.
10.
NakayamaEE, HoshinoY, XinX, LiuH, GotoM, WatanabeN, TaguchiH, HitaniA, Kawana-TachikawaA, FukushimaM, YamadaK, SugiuraW, OkaSI, AjisawaA, SatoH, TakebeY, NakamuraT, NagaiY, IwamotoA, ShiodaT. Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J Virol, 2000; 74:5452–5459.
11.
LiYG, IwabuY, WarachitJ, KinomotoM, IbrahimMS, TsujiS, MukaiT, KameokaM, TokunagaK, SataT, IkutaK. Interleukin-4 up-regulates T-tropic human immunodeficiency virus type 1 transcription in primary CD4+ CD38+ T-lymphocyte subset. Microbiol Immunol, 2005; 49:155–165.
12.
NapolitanoLA, GrantRM, DeeksSG, SchmidtD, De RosaSC, HerzenbergLA, HerndierBG, AnderssonJ, McCuneJM. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: Implications for T-cell homeostasis. Nat Med, 2001; 7:73–79.
13.
BoulasselMR, YoungM, RoutyJP, SekalyRP, TremblayC, RouleauD. Circulating levels of IL-7 but not IL-15, IGF-1, and TGF-β are elevated during primary HIV-1 infection. HIV Clin Trials, 2004; 5:357–359.
14.
StylianouE, AukrustP, KvaleD, MullerF, FrolandSS. IL-10 in HIV infection: Increasing serum IL-10 levels with disease progression–down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol, 1999; 116:115–120.
15.
AmicosanteM, PocciaF, GioiaC, MontesanoC, TopinoS, MartiniF, NarcisoP, PucilloLP, D'OffiziG. Levels of interleukin-15 in plasma may predict a favorable outcome of structured treatment interruption in patients with chronic human immunodeficiency virus infection. J Infect Dis, 2003; 188:661–665.
16.
AhmadR, SindhuST, TomaE, MorissetR, AhmadA. Studies on the production of IL-15 in HIV-infected/AIDS patients. J Clin Immunol, 2003; 23:81–90.
17.
TorreD, SperanzaF, MarteganiR, PuglieseA, CastelliF, BasilicoC, BiondiG. Circulating levels of IL-18 in adult and paediatric patients with HIV-1 infection. AIDS, 2000; 14:2211–2212.
18.
IannelloA, SamaraniS, DebbecheO, AhmadR, BoulasselMR, TremblayC, TomaE, RoutyJP, AhmadA. Potential role of interleukin-18 in the immunopathogenesis of AIDS: Involvement in fratricidal killing of NK cells. J Virol, 2009; 83:5999–6010.
19.
Wiercinska-DrapaloA, FlisiakR, JaroszewiczJ, ProkopowiczD. Increased plasma transforming growth factor-β1 is associated with disease progression in HIV-1-infected patients. Viral Immunol, 2004; 17:109–113.
20.
PizzoloG, VinanteF, MorosatoL, NadaliG, ChilosiM, GandiniG, SiniccoA, RaiteriR, SemenzatoG, SteinHet al.High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS, 1994; 8:741–745.
21.
RizzardiGP, BarcelliniW, TambussiG, LilloF, MalnatiM, PerrinL, LazzarinA. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: Correlation with HIV-1 RNA and the clinical outcome. AIDS, 1996; 10:F45–50.
22.
PizzoloG, VinanteF, NadaliG, KramperaM, MorosatoL, ChilosiM, RaiteriR, SiniccoA. High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol, 1997; 108:251–253.
BettsMR, NasonMC, WestSM, De RosaSC, MiguelesSA, AbrahamJ, LedermanMM, BenitoJM, GoepfertPA, ConnorsM, RoedererM, KoupRA. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood, 2006; 107:4781–4789.
25.
StaceyAR, NorrisPJ, QinL, HaygreenEA, TaylorE, HeitmanJ, LebedevaM, DeCampA, LiD, GroveD, SelfSG, BorrowP. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol, 2009; 83:3719–3733.
26.
SongW, WilsonCM, AllenS, WangC, LiY, KaslowRA, TangJ. Interleukin 18 and human immunodeficiency virus type 1 infection in adolescents and adults. Clin Exp Immunol, 2006; 144:117–124.
27.
ShaoW, TangJ, SongW, WangC, LiY, WilsonCM, KaslowRA. CCL3L1 and CCL4L1: Variable gene copy number in adolescents with and without human immunodeficiency virus type 1 (HIV-1) infection. Genes Immun, 2007; 8:224–231.
28.
RogersAS, FuttermanDK, MoscikiAB, WilsonCM, EllenbergJ, VermundSH. The REACH project of the adolescent medicine HIV/AIDS research network: Design, methods, and selected characteristics of participants. J Adolesc Health, 1998; 22:300–311.
29.
WilsonCM, HouserJ, PartlowC, RudyBJ, FuttermanDC, FriedmanLB. The REACH (Reaching for Excellence in Adolescent Care and Health) project: Study design, methods, and population profile. J Adolesc Health, 2001; 29:8–18.
30.
HollandCA, MaY, MoscickiB, DurakoSJ, LevinL, WilsonCM. Seroprevalence and risk factors of hepatitis B, hepatitis C, and human cytomegalovirus among HIV-infected and high-risk uninfected adolescents: Findings of the REACH Study. Adolescent Medicine HIV/AIDS Research Network. Sex Transm Dis, 2000; 27:296–303.
31.
TangJ, WilsonCM, MelethS, MyracleA, LobashevskyE, MulliganMJ, DouglasSD, KorberB, VermundSH, KaslowRA. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS, 2002; 16:2275–2284.
32.
ShresthaS, AissaniB, SongW, WilsonCM, KaslowRA, TangJ. Host genetics and HIV-1 viral load set-point in African-Americans. AIDS, 2009; 23:673–677.
33.
TangJ. Chemokine receptor, ligand genes. Genetic Susceptibility to Infectious Diseases. KaslowRA, McNichollJM, HillAVS. Oxford University Press: New York, 2008; 247–262.
34.
DouglasSD, DurakoS, SullivanKE, CamarcaM, MoscickiAB, WilsonCM. TH1 and TH2 cytokine mRNA and protein levels in human immunodeficiency virus (HIV)-seropositive and HIV-seronegative youths. Clin Diagn Lab Immunol, 2003; 10:399–404.
35.
LoweGD. The relationship between infection, inflammation, and cardiovascular disease: An overview. Ann Periodontol, 2001; 6:1–8.
36.
SignorelliSS, MazzarinoMC, SpandidosDA, MalaponteG. Proinflammatory circulating molecules in peripheral arterial disease. Int J Mol Med, 2007; 20:279–286.
37.
ManettiR, AnnunziatoF, BiagiottiR, GiudiziMG, PiccinniMP, GiannariniL, SampognaroS, ParronchiP, VinanteF, PizzoloG, MaggiE, RomagnaniS. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+ CD30+ T cell clones in human immunodeficiency virus infection. J Exp Med, 1994; 180:2407–2411.
38.
SadeghiM, SusalC, DanielV, NaujokatC, ZimmermannR, Huth-KuhneA, OpelzG. Decreasing soluble CD30 and increasing IFN-γ plasma levels are indicators of effective highly active antiretroviral therapy. AIDS Res Hum Retroviruses, 2007; 23:886–890.
39.
JiJ, SahuGK, BracialeVL, CloydMW. HIV-1 induces IL-10 production in human monocytes via a CD4-independent pathway. Int Immunol, 2005; 17:729–736.
40.
BrooksDG, TrifiloMJ, EdelmannKH, TeytonL, McGavernDB, OldstoneMB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med, 2006; 12:1301–1309.
41.
AlterG, KavanaghD, RihnS, LuteijnR, BrooksD, OldstoneM, van LunzenJ, AltfeldM. IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection. J Clin Invest, 2010; 120:1905–1913.
42.
JirilloE, CovelliV, BrandonisioO, MunnoI, De SimoneC, MastroianniCM, AntonaciS, RiccioP. HIV-infection and in vivo lipopolysaccharide-induced release of cytokines. An amplified mechanism of damage to the host. Acta Neurol (Napoli), 1991; 13:188–196.
43.
BrenchleyJM, PriceDA, SchackerTW, AsherTE, SilvestriG, RaoS, KazzazZ, BornsteinE, LambotteO, AltmannD, BlazarBR, RodriguezB, Teixeira-JohnsonL, LandayA, MartinJN, HechtFM, PickerLJ, LedermanMM, DeeksSG, DouekDC. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med, 2006; 12:1365–1371.
44.
DouekD. HIV disease progression: Immune activation, microbes, and a leaky gut. Top HIV Med, 2007; 15:114–117.
45.
HuntPW, BrenchleyJ, SinclairE, McCuneJM, RolandM, Page-ShaferK, HsueP, EmuB, KroneM, LampirisH, DouekD, MartinJN, DeeksSG. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis, 2008; 197:126–133.
46.
BaroncelliS, GalluzzoCM, PirilloMF, ManciniMG, WeimerLE, AndreottiM, AmiciR, VellaS, GiulianoM, PalmisanoL. Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50 copies/ml HIV-1 RNA. J Clin Virol, 2009; 46:367–370.
47.
PapasavvasE, PistilliM, ReynoldsG, BuckiR, AzzoniL, ChehimiJ, JanmeyPA, DiNubileMJ, OndercinJ, KostmanJR, MounzerKC, MontanerLJ. Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS, 2009; 23:369–375.
48.
LienE, AukrustP, SundanA, MullerF, FrolandSS, EspevikT. Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: Correlation to disease progression and clinical events. Blood, 1998; 92:2084–2092.
49.
RyanLA, ZhengJ, BresterM, BohacD, HahnF, AndersonJ, RatanasuwanW, GendelmanHE, SwindellsS. Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J Infect Dis, 2001; 184:699–706.
50.
eBioscience: Cytokines––Master Regulators of the Immune System. www.ebioscience.com/ebioscience/whatsnew/pdf/Cytokines.pdf. 2010 August 18.
51.
eBioscience: Human CD & Other Cellular Antigens. http://www.ebioscience.com/ebioscience/contact.asp. 2010 August 18.
52.
RubbertA, WeissmanD, CombadiereC, PettroneKA, DaucherJA, MurphyPM, FauciAS. Multifactorial nature of noncytolytic CD8+ T cell-mediated suppression of HIV replication: Beta-chemokine-dependent and -independent effects. AIDS Res Hum Retroviruses, 1997; 13:63–69.
53.
BernsteinHB, KinterAL, JacksonR, FauciAS. Neonatal natural killer cells produce chemokines and suppress HIV replication in vitro. AIDS Res Hum Retroviruses, 2004; 20:1189–1195.
54.
ChiravuriM, AgarraberesF, MathieuSL, LeeH, HuberBT. Vesicular localization and characterization of a novel post-proline-cleaving aminodipeptidase, quiescent cell proline dipeptidase. J Immunol, 2000; 165:5695–5702.
55.
TrautmannL, JanbazianL, ChomontN, SaidEA, WangG, GimmigS, BessetteB, BoulasselMR, DelwartE, SepulvedaH, BalderasRS, RoutyJP, HaddadEK, SekalyRP. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med, 2006; 12:1198–1202.
56.
FreemanGJ, WherryEJ, AhmedR, SharpeAH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med, 2006; 203:2223–2227.
57.
PetrovasC, CasazzaJP, BrenchleyJM, PriceDA, GostickE, AdamsWC, PrecopioML, SchackerT, RoedererM, DouekDC, KoupRA. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med, 2006; 203:2281–2292.
58.
DayCL, KaufmannDE, KiepielaP, BrownJA, MoodleyES, ReddyS, MackeyEW, MillerJD, LeslieAJ, DePierresC, MncubeZ, DuraiswamyJ, ZhuB, EichbaumQ, AltfeldM, WherryEJ, CoovadiaHM, GoulderPJ, KlenermanP, AhmedR, FreemanGJ, WalkerBD. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 2006; 443:350–354.
59.
PaulME, ShearerWT, KozinetzCA, LewisDE. Comparison of CD8(+) T-cell subsets in HIV-infected rapid progressor children versus non-rapid progressor children. J Allergy Clin Immunol, 2001; 108:258–264.
60.
ResinoS, BellonJM, GurbindoMD, Munoz-FernandezMA. CD38 expression in CD8+ T cells predicts virological failure in HIV type 1-infected children receiving antiretroviral therapy. Clin Infect Dis, 2004; 38:412–417.
61.
WilsonCM, EllenbergJH, DouglasSD, MoscickiAB, HollandCA. CD8+ CD38+ T cells but not HIV type 1 RNA viral load predict CD4+ T cell loss in a predominantly minority female HIV+ adolescent population. AIDS Res Hum Retroviruses, 2004; 20:263–269.
62.
RudyBJ, LindseyJC, FlynnPM, BoschRJ, WilsonCM, HughesME, DouglasSD. Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: Week 60 results from the PACTG 381 cohort. AIDS Res Hum Retroviruses, 2006; 22:213–221.
63.
ListEO, BerrymanDE, BowerB, Sackmann-SalaL, GosneyE, DingJ, OkadaS, KopchickJJ. The use of proteomics to study infectious diseases. Infect Disord Drug Targets, 2008; 8:31–45.
64.
KalayjianRC, MachekanoRN, RizkN, RobbinsGK, GandhiRT, RodriguezBA, PollardRB, LedermanMM, LandayA. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis, 2010; 201:1796–1805.
65.
PatelK, BenhamouY, YoshidaEM, KaitaKD, ZeuzemS, TorbensonM, PulkstenisE, SubramanianGM, McHutchisonJG. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat, 2009; 16:178–186.
66.
HelbigKJ, RuszkiewiczA, LanfordRE, BerzsenyiMD, HarleyHA, McCollSR, BeardMR. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro. J Virol, 2009; 83:836–846.
67.
ZeremskiM, DimovaR, BrownQ, JacobsonIM, MarkatouM, TalalAH. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis, 2009; 200:1774–1780.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
